Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients

被引:4
|
作者
Wang, Miao [1 ,2 ]
Duan, Bao-ling [2 ]
Yuan, Yin-jin [3 ]
Su, Xia [1 ]
Zheng, Hang [1 ]
Wang, Fu-sheng [2 ]
Sun, He [1 ]
机构
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, 92 Weijin Rd, Tianjin 300072, Peoples R China
[2] North China Pharmaceut Grp Corp, New Drug Res & Dev Ctr, Natl Engn Res Ctr Microbial Med, Shijiazhuang, Hebei, Peoples R China
[3] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China
关键词
renal transplant patients; healthy subjects; population pharmacokinetics; sirolimus; cyclosporine; CLINICAL PHARMACOKINETICS; PEDIATRIC-PATIENTS; RAPAMYCIN; SAFETY; CYCLOSPORINE; VOLUNTEERS; RECIPIENTS; REJECTION; EFFICACY; ADULT;
D O I
10.5414/CP202499
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To identify the factors affecting the pharmacokinetics (PKs) of sirolimus in healthy Chinese subjects and renal transplant patients. Methods: A population PK model of sirolimus was constructed using dense data from 22 healthy volunteers and sparse data from 105 renal transplant patients. Results: The data were well described by a two-compaitment model with first-order absorption. The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively. The CL/F in renal transplant patients was 45.5% lower than that in healthy subjects. Based on the final model, CL/F decreased significantly with increasing cyclosporine (CsA) daily dose and age. A decrease of 7.3% in CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in CL/F for every 20-year increase in age was observed. Moreover, V2/F increased significantly with increasing serum creatinine in our study. However, the range of serum creatinine concentration and the interindividual variability for V2/F are large. Conclusion: This is the first study to characterize the population PKs of sirolimus using a two-compartment model in healthy Chinese subjects and renal transplant patients. A decrease of 7.3% in the sirolimus CL/F for every 100-mg increase in the CsA daily dose and a decrease of 34.2% in the sirolimus CL/F for every 20-year increase in age was observed, which allowed us to better optimize sirolimus dosing regimens in Chinese renal transplant patients.
引用
收藏
页码:433 / 441
页数:9
相关论文
共 50 条
  • [41] Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects
    Troconiz, Inaki F.
    Cendros, Josep-Maria
    Peraire, Concepcion
    Ramis, Joaquim
    Garrido, Maria J.
    Boscani, Paolo F.
    Obach, Rosendo
    CLINICAL PHARMACOKINETICS, 2009, 48 (01) : 51 - 62
  • [42] Population pharmacokinetic analysis of rimonabant in healthy subjects.
    Ferron, GM
    Grandison, M
    Lockwood, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P43 - P43
  • [43] Population pharmacokinetics of sirolimus in kidney transplant patients
    Ferron, GM
    Mishina, EV
    Zimmerman, JJ
    Jusko, WJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (04) : 416 - 428
  • [44] Optimized population pharmacokinetic model of cyclosporin in stable renal transplant patients.
    Rousseau, A
    Léger, F
    Saint-Marcoux, F
    Debord, J
    Le Meur, Y
    Buchler, M
    Marquet, P
    THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 514 - 514
  • [45] Early experience with conversion to sirolimus in a pediatric renal transplant population
    Powell, Harley R.
    Kara, Tonya
    Jones, Colin L.
    PEDIATRIC NEPHROLOGY, 2007, 22 (10) : 1773 - 1777
  • [46] Early experience with conversion to sirolimus in a pediatric renal transplant population
    Harley R. Powell
    Tonya Kara
    Colin L. Jones
    Pediatric Nephrology, 2007, 22 : 1773 - 1777
  • [47] Pharmacokinetic and Pharmacodynamic Study of Bivalirudin in Healthy Chinese Adult Subjects
    Huang, Yu-hong
    Huang, Ji-han
    Gao, Xiu-mei
    Li, Lu-jin
    Pan, Gui-xiang
    Sun, Jin-xia
    Wang, Bao-he
    Zheng, Qing-shan
    Zhang, Bo-li
    LATIN AMERICAN JOURNAL OF PHARMACY, 2014, 33 (06): : 935 - 941
  • [48] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Kun Wang
    Lingge Feng
    Jiayi Zhang
    Quanfei Zou
    Fengyan Xu
    Zhongyi Sun
    Fuxing Tang
    Li Chen
    Clinical Pharmacokinetics, 2023, 62 : 1413 - 1425
  • [49] Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients
    Nassim Djebli
    Annick Rousseau
    Guillaume Hoizey
    Jean-Philippe Rerolle
    Olivier Toupance
    Yann Le Meur
    Pierre Marquet
    Clinical Pharmacokinetics, 2006, 45 : 1135 - 1148
  • [50] Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus
    Wang, Kun
    Feng, Lingge
    Zhang, Jiayi
    Zou, Quanfei
    Xu, Fengyan
    Sun, Zhongyi
    Tang, Fuxing
    Chen, Li
    CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1413 - 1425